Pharnext, Developer of CMT1A Treatment Candidate PXT3003, Raises 16 Million Euros
News
Pharnext SA — the French biopharmaceutical company developing PXT3003 as a therapeutic candidate to treat Charcot-Marie-Tooth disease type 1A (CMT1A) — announced that it has successfully raised 16 million euros, ... Read more